{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:06Z","timestamp":1793889786741,"version":"4.8.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biohaven"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the long-term safety, tolerability and effectiveness of rimegepant, 75 mg orally disintegrating tablet, for the acute treatment of migraine in Chinese adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 3, multicenter, open-label, single-arm study enrolled Chinese adults with a \u22651 year history of migraine (with or without aura), 6\u201318 moderate-to-severe migraine attacks\/month within three months before a screening visit and at least six migraine days during a 30-day observation phase (OP). After the OP, eligible participants took rimegepant as needed (maximum one tablet per day) at the onset of mild-to-severe migraine attack for a long-term treatment (LTT) of 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 240 participants were treated and 208 (86.3%) completed the study. During LTT, 203 (84.6%) participants reported \u22651 treatment-emergent adverse event (TEAE) and 46 (19.2%) reported \u22651 TEAE considered to be rimegepant-related. There were no rimegepant-related serious AEs or rimegepant-related TEAEs that led to treatment interruption or discontinuation. Mean reduction from the OP in monthly migraine days was observed as early as the first four weeks (\u22121.7; 95% confidence interval = \u22122.2 to \u22121.2), with an overall mean reduction of \u22124.4 (95% confidence interval = \u22124.9 to \u22123.9) days across LTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rimegepant had a favorable long-term safety profile, was well tolerated in Chinese participants, and a reduction in the number of monthly migraine days was observed during the LLT.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration:<\/jats:bold>\n                      ClinicalTrials.gov identifier: NCT05371652\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251371686","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:32:51Z","timestamp":1760027571000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3519-1746","authenticated-orcid":false,"given":"Mingjie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yan'an University Xianyang Hospital, Xianyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Friendship Hospital of Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wuhan Third Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huailian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingmin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Lu","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-1248","authenticated-orcid":false,"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[{"name":"Internal Medicine, Pfizer Inc, Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[{"name":"Internal Medicine, Pfizer Inc, Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5138-0499","authenticated-orcid":false,"given":"Qi","family":"Zhong","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Han","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1048-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12353"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221141686"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00126-6"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01731-4"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/25158163221075596"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00086.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01156.x"},{"key":"e_1_3_3_14_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976."},{"key":"e_1_3_3_15_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services National Institutes of Health National Cancer Institute. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (accessed 1 December 2024)."},{"key":"e_1_3_3_16_2","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. Published: September 2023. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_26_1_English.pdf (accessed 1 December 2024)."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S453806"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.124"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01288.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03497.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0875-x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-1084-y"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01243-5"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13588"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01775-6"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13907"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S456006"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251371686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251371686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251371686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:33Z","timestamp":1777387593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251371686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/03331024251371686"],"URL":"https:\/\/doi.org\/10.1177\/03331024251371686","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"03331024251371686"}}